Uwe Liebchen
Overview
Explore the profile of Uwe Liebchen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wustrow V, Grafe C, Graf H, Scheiermann P, Paal M, Vogeser M, et al.
Biomedicines
. 2025 Feb;
13(2).
PMID: 40002832
: Patients with shock suffer from hyperlactatemia, which can lead to endothelial dysfunction. The use of the adsorber Cytosorb (CS) is recommended in these patients as it may contribute to...
2.
Chiriac U, Liebchen U, Frey O, Lanzinger H, Klein S, Hoppe-Tichy T, et al.
Antibiotics (Basel)
. 2024 Nov;
13(11).
PMID: 39596796
Increasing evidence suggests that dalbavancin is an effective long-term treatment for ventricular assist device (VAD) infections, with various prolonged dosing regimens currently in use. This retrospective study aimed to assess...
3.
Bucher V, Graf H, Zander J, Liebchen U, Hackner D, Grafe C, et al.
Biomedicines
. 2024 Nov;
12(11).
PMID: 39595003
Introduction: Angiopoietin II (Ang-II) plays a pivotal role in the development of microcirculatory dysfunction as it provokes endothelial barrier disruption in patients with sepsis or septic shock. In particular, those...
4.
Brozat C, Zoller M, Frank S, Bruegel M, Grafe C, Rebholz D, et al.
Blood Purif
. 2024 Nov;
54(2):93-101.
PMID: 39510059
Introduction: Adsorption devices like CytoSorb® (CS) are increasingly used in critically ill patients. However, potential adverse effects have not been sufficiently investigated. The aim of this post hoc analysis of...
5.
Wicha S, Kinast C, Munchow M, Wittova S, Greppmair S, Kunzelmann A, et al.
Antimicrob Agents Chemother
. 2024 Nov;
68(12):e0146824.
PMID: 39503486
No abstract available.
6.
Naehrig S, Shad C, Breuling M, Goetschke M, Habler K, Sieber S, et al.
J Pers Med
. 2024 Oct;
14(10).
PMID: 39452571
Background/objectives: Elexacaftor, tezacaftor, and ivacaftor (ETI) have significantly improved lung function in people with cystic fibrosis (pwCF). Despite exceptional improvements in most cases, treatment-related inter-subject variability and drug-drug interactions that...
7.
Grafe C, Graf H, Wustrow V, Liebchen U, Conter P, Paal M, et al.
Sci Rep
. 2024 Sep;
14(1):21762.
PMID: 39294181
Bilirubin is one of the most frequently used laboratory values to monitor critically ill patients with cholestatic liver dysfunction. Besides bilirubin, toxic bile acids (TBAs), which may cause severe organ...
8.
Kipka H, Liebchen U, Hubner M, Hofner G, Frey O, Wanner K, et al.
Front Cardiovasc Med
. 2024 Aug;
11:1406338.
PMID: 39175630
Background: The inotropic drug levosimendan is often used as an individualized therapeutic approach perioperatively in cardiac surgery patients with cardiopulmonary bypass (CPB). Data regarding serum concentrations of levosimendan and its...
9.
Graf H, Grafe C, Bruegel M, Happich F, Wustrow V, Wegener A, et al.
Infect Dis Ther
. 2024 Aug;
13(9):2089-2101.
PMID: 39154299
Introduction: The release of pro-inflammatory cytokines in critically ill patients with sepsis leads to endothelial dysfunction resulting in cardiocirculatory insufficiency. Their extracorporeal elimination using the cytokine adsorber CytoSorb (CS) (adsorption...
10.
Schatz L, Greppmair S, Kunzelmann A, Starp J, Brinkmann A, Roehr A, et al.
Int J Antimicrob Agents
. 2024 Aug;
64(4):107305.
PMID: 39146997
Objectives: Piperacillin (PIP)/tazobactam is a frequently prescribed antibiotic; however, over- or underdosing may contribute to toxicity, therapeutic failure, and development of antimicrobial resistance. An external evaluation of 24 published PIP-models...